Defining the chemotherapeutic targets of histone deacetylase inhibitors

Annals of the New York Academy of Sciences

Volumn 1030, Issue , 2004, Pages 627-635

  Gabrielli, Brian ^a   Warrener, Robyn ^a   Burgess, Andrew ^a   Beamish, Heather ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cell cycle checkpoint; Centromere; Heterochromatin; Histone deacetylase inhibitor; Mitosis

Indexed keywords

ANTIINFECTIVE AGENT; AZELAIC BISHYDROXAMIC ACID; BUTYRIC ACID; GENE PRODUCT; HISTONE; HISTONE DEACETYLASE INHIBITOR; SUBERIC BISHYDROXAMIC ACID; UNCLASSIFIED DRUG; VORINOSTAT;

CENTROMERE; CHROMATIN STRUCTURE; CONFERENCE PAPER; CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; EUCHROMATIN; HELA CELL; HETEROCHROMATIN; HUMAN; HUMAN CELL; MELANOMA CELL; TRANSCRIPTION REGULATION;

EID: 15044340171     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1329.073     Document Type: Conference Paper

References (27)

1. MARKS, P.A., V.M. RICHON, R. BRESLOW, et al. 2001. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 13: 477-483.
2. GABRIELLI, B.C., R.W. JOHNSTONE & N.A. SAUNDERS. 2002. Identifying molecular targets mediating the anticancer activity of histone deacetylase inhibitors: a work in progress. Curr. Cancer Drug Targets 2: 337-353.
3. PARSONS, P.G., C. HANSEN, D.P. FAIRLIE, et al. 1997. Tumor selectivity and transcriptional activation by azelaic bishydroxamic acid in human melanocytic cells. Biochem. Pharmacol. 53: 1719-1724.
4. QIU, L., M.J. KELSO, C. HANSEN, et al. 1999. Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br. J. Cancer 80: 1252-1258.
5. QIU, L., A. BURGESS, D.P. FAIRLIE, et al. 2000. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol. Biol. Cell 11: 2069-2083.
6. BURGESS, A.J., S. PAVEY, R. WARRENER, et al. 2001. Up-regulation of p21(WAF1/ CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. Mol. Pharmacol. 60: 828-837.
7. WARRENER, R., H. BEAMISH, A. BURGESS, et al. 2003. Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints. FASEB J. 17: 1550-1552.
8. RICHON, V.M., T.W. SANDHOFF, R.A. RIFKIND, et al. 2000. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. USA 97: 10014-10019.
9. ARCHER, S.Y., S. MENG, A. SHEI, et al. 1998. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc. Natl. Acad. Sci. USA 95: 6791-6796.
10. SOWA, Y., T. ORITA, S. MINAMIKAWA, et al. 1997. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem. Biophys. Res. Commun. 241: 142-150.
11. SAMBUCETTI, L.C.,D.D. FISCHER, S. ZABLUDOFF, et al. 1999. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J. Biol. Chem. 274: 34940-34947.
12. KIM, Y.B., K.H. LEE, K. SUGITA, et al. 1999. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene 18: 2461-2470.
13. KRAUER, K.G., A. BURGESS, M. BUCK, et al. 2004. The EBNA-3 gene family proteins disrupt the G2/M checkpoint. Oncogene 23: 1342-1353.
14. GLASER, K.B., M.J. STAYER, J.F. WARING, et al. 2003. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2: 151-163.
15. CHAMBERS, A.E., S. BANERJEE, T. CHAPLIN, et al. 2003. Histone acetylation-mediated regulation of genes in leukaemic cells. Eur. J. Cancer 39: 1165-1175.
16. SATO, N., N. FUKUSHIMA, A. MAITRA, et al. 2003. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays: histone acetylation-mediated regulation of genes in leukaemic cells. Cancer Res. 63: 3735-3742.
17. TADDEI, A., C. MAISON, D. ROCHE, et al. 2001. Reversible disruption of pericentric heterochromatin and centromere function by inhibiting deacetylases. Nat. Cell Biol. 3: 114-120.
18. WASSMANN, K. & R. BENEZRA. 2001. Mitotic checkpoints: from yeast to cancer. Curr. Opin. Genet. Dev. 11: 83-90.
19. KOUZARIDES, T. 2000. Acetylation: a regulatory modification to rival phosphorylation? EMBO J. 19: 1176-1179.
20. SOBEL, R.E., R.G. COOK, C.A. PERRY, et al. 1995. Conservation of deposition-related acetylation sites in newly synthesized histones H3 and H4. Proc. Natl. Acad. Sci. USA 92: 1237-1241.
21. MELLO, J.A. & G. ALMOUZNI. 2001. The ins and outs of nucleosome assembly. Curr. Opin. Genet. Dev. 11: 136-141.
22. TADDEI, A., D. ROCHE, J.B. SIBARITA, et al. 1999. Duplication and maintenance of heterochromatin domains. J. Cell Biol. 147: 1153-1166.
23. SCHAAR, B.T., G.K. CHAN, P. MADDOX, et al. 1997. CENP-E function at kinetochores is essential for chromosome alignment. J. Cell Biol. 139: 1373-1382.
24. TAYLOR, S.S. & F. MCKEON. 1997. Kinetochore localization of murine Bub1 is required for normal mitotic timing and checkpoint response to spindle damage. Cell 89: 727-735.
25. HOWMAN, E.V., K.J. FOWLER, A.J. NEWSON, et al. 2000. Early disruption of centromeric chromatin organization in centromere protein A (Cenpa) null mice. Proc. Natl. Acad. Sci. USA 97: 1148-1153.
26. PIPERNO, G., M. LeDizet & X.J. Chang. 1987. Microtubules containing acetylated α-tubulin in mammalian cells in culture. J. Cell Biol. 104: 289-302.
27. HUBBERT, C., A. GUARDIOLA, R. SHAO, et al. 2002. HDAC6 is a microtubule-associated deacetylase. Nature 417: 455-458.